DE3390212C2 - - Google Patents

Info

Publication number
DE3390212C2
DE3390212C2 DE3390212T DE3390212T DE3390212C2 DE 3390212 C2 DE3390212 C2 DE 3390212C2 DE 3390212 T DE3390212 T DE 3390212T DE 3390212 T DE3390212 T DE 3390212T DE 3390212 C2 DE3390212 C2 DE 3390212C2
Authority
DE
Germany
Prior art keywords
acyl
radical
hydrogen
aliphatic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3390212T
Other languages
German (de)
English (en)
Other versions
DE3390212T1 (de
Inventor
Hector F Deluca
Heinrich K Schnoes
Jacek W Morzycki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of DE3390212T1 publication Critical patent/DE3390212T1/de
Application granted granted Critical
Publication of DE3390212C2 publication Critical patent/DE3390212C2/de
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20Free hydroxyl or mercaptan
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE19833390212 1982-09-20 1983-09-12 Hydroxyvitamin D↓2↓-Verbindungen und Verfahren zu deren Herstellung Granted DE3390212T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/420,191 US4448721A (en) 1982-09-20 1982-09-20 Hydroxyvitamin D2 compounds and process for preparing same
PCT/US1983/001393 WO1984001155A1 (en) 1982-09-20 1983-09-12 Hydroxyvitamin d2 compounds and process for preparing them

Publications (2)

Publication Number Publication Date
DE3390212T1 DE3390212T1 (de) 1984-11-29
DE3390212C2 true DE3390212C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-10-31

Family

ID=23665448

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3348322A Expired - Lifetime DE3348322C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-09-20 1983-09-12
DE19833390212 Granted DE3390212T1 (de) 1982-09-20 1983-09-12 Hydroxyvitamin D↓2↓-Verbindungen und Verfahren zu deren Herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE3348322A Expired - Lifetime DE3348322C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-09-20 1983-09-12

Country Status (11)

Country Link
US (1) US4448721A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0119251A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (6) JPS59501746A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1283422C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH671222A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3348322C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (3) FR2540869B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB2127023B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE56174B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL69763A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1984001155A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036061A (en) * 1983-05-09 1991-07-30 Deluca Hector F Process for the preparation of 1 alpha,25-dihydroxylated vitamin D2 and related compounds
US4505906A (en) * 1984-01-30 1985-03-19 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 isomers
US5120722A (en) * 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
US4588528A (en) * 1984-05-31 1986-05-13 Wisconsin Alumni Research Foundation 1,24-dihydroxy-Δ22 -vitamin D3 and process for preparing same
US4857518A (en) * 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
WO1986002078A1 (en) * 1984-10-04 1986-04-10 Wisconsin Alumni Research Foundation Vitamin d derivatives and methods for preparing same
US5225579A (en) * 1988-03-16 1993-07-06 Hoxan Corporation Method of manufacturing vitamin D2, Vitamin D3, activated type vitamin D2, activated type vitamin D3, and their derivatives
US5260290A (en) * 1990-02-14 1993-11-09 Wisconsin Alumni Research Foundation Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
US5030772A (en) * 1990-02-14 1991-07-09 Deluca Hector F Process for preparing vitamin D2 compounds and the corresponding 1 α-hydroxylated derivatives
IN171426B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-02-14 1992-10-10 Wisconsin Alumni Res Found
US5063234A (en) * 1990-05-25 1991-11-05 Eli Lilly And Company Method of inhibiting demineralization of bone
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
WO1992012165A1 (en) * 1991-01-08 1992-07-23 Lunar Corporation METHODS FOR PREPARATION AND USE OF 1α,24-DIHYDROXY VITAMIN D¿2?
CA2129120A1 (en) * 1992-01-29 1993-08-05 Joyce C. Knutson 1.alpha.-hydroxy-24-epi-vitamin d4
TW267161B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1992-11-20 1996-01-01 Hoffmann La Roche
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
JP4514452B2 (ja) * 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション A2aアゴニスト活性を有する2−プロピルアデノシン・アナログおよびその組成物
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7947682B2 (en) * 2004-12-29 2011-05-24 University Of Southern California Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents
WO2007092755A2 (en) 2006-02-03 2007-08-16 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
CA2655499C (en) 2006-06-21 2015-10-27 Proventiv Therapeutics, Llc Method of treating and preventing secondary hyperparathyroidism_with vitamin d repletion and vitamin d replacemnt therapies
EP2148684B1 (en) 2007-04-25 2013-01-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
JP5501956B2 (ja) 2007-04-25 2014-05-28 シトクロマ インコーポレイテッド ビタミンd化合物およびワックス状担体を含有する制御放出性経口組成物
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
KR101852042B1 (ko) 2008-04-02 2018-04-25 사이토크로마 인코포레이티드 비타민 d 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
US9212136B2 (en) * 2008-07-22 2015-12-15 Azad Pharmaceuticals Ingredients Ag Methods for producing paricalcitol
JP5932339B2 (ja) * 2009-01-27 2016-06-08 バーグ エルエルシー 化学療法に付随する副作用を軽減するためのビタミンd3およびその類似体
BR112012003372A2 (pt) 2009-08-14 2019-09-24 Berg Biosystems Llc vitamina d3 e análogos da mesma para o tratamento de alopecia.
CN105796530A (zh) 2010-03-29 2016-07-27 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
CA2698160C (en) * 2010-03-30 2017-07-25 Alphora Research Inc. Stabilized doxercalciferol and process for manufacturing the same
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
CN105492081A (zh) 2013-05-29 2016-04-13 博格有限责任公司 使用维生素d预防或减轻化疗诱发的脱发
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3436026A1 (en) 2016-03-28 2019-02-06 OPKO Ireland Global Holdings, Ltd. Methods of vitamin d treatment
CN115947678B (zh) * 2023-03-10 2024-01-16 成都诺森医学检验有限公司 稳定同位素2h(d)标记25-羟基维生素d2的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052283B (it) * 1968-07-01 1981-06-20 Wisconsin Alumni Res Found Processo per preparare composti del calciferolo e relativi composti
US3880894A (en) * 1974-05-24 1975-04-29 Wisconsin Alumni Res Found 1,25-Dihydroxyergocalciferol
US4105660A (en) * 1977-06-29 1978-08-08 Merck & Co., Inc. Preparation of 3β-hydroxy-27-norcholest-5,7-dien-25-one
US4145346A (en) * 1977-10-03 1979-03-20 Merck & Co., Inc. Preparation of 3β-hydroxy-27-norcholest-5-ene-25-one and intermediates thereof
US4229358A (en) * 1978-07-26 1980-10-21 Wisconsin Alumni Research Foundation Fluorovitamin D compounds and processes for their preparation
US4188345A (en) * 1978-07-26 1980-02-12 Wisconsin Alumni Research Foundation Fluorovitamin D compounds and processes for their preparation
US4265822A (en) * 1979-09-10 1981-05-05 Wisconsin Alumni Research Foundation Process for preparing 1-hydroxylated vitamin D compounds from 5,6-trans-vitamin D compounds
DE3048698A1 (de) * 1980-12-23 1982-07-15 Wisconsin Alumni Research Foundation, 53707 Madison, Wis. Verfahren zur herstellung einer 1(alpha)-hydroxylierten vitamin-d-verbindung, ausgehend von einer 5,6-trans-vitamin-d-verbindung

Also Published As

Publication number Publication date
IE832203L (en) 1984-03-20
JPH02209887A (ja) 1990-08-21
GB2127023A (en) 1984-04-04
JPH0610187B2 (ja) 1994-02-09
JPH0518840B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-03-15
GB8417477D0 (en) 1984-08-15
FR2555172B1 (fr) 1987-08-07
IL69763A (en) 1987-01-30
CA1283422C (en) 1991-04-23
FR2555172A1 (fr) 1985-05-24
CH671222A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-08-15
JPH02209864A (ja) 1990-08-21
WO1984001155A1 (en) 1984-03-29
FR2555173B1 (fr) 1989-04-07
JPH0435458B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-06-11
JPH02209863A (ja) 1990-08-21
IE56174B1 (en) 1991-05-08
FR2555173A1 (fr) 1985-05-24
EP0119251A1 (en) 1984-09-26
JPH0518839B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-03-15
GB2142922B (en) 1986-08-28
GB8325131D0 (en) 1983-10-19
US4448721A (en) 1984-05-15
GB2127023B (en) 1987-07-08
DE3390212T1 (de) 1984-11-29
JPH02209888A (ja) 1990-08-21
JPS59501746A (ja) 1984-10-18
FR2540869A1 (fr) 1984-08-17
GB2142922A (en) 1985-01-30
JPH0443916B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-07-20
FR2540869B1 (fr) 1988-04-15
DE3348322C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-07-25
JPH02209862A (ja) 1990-08-21
JPH0434540B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-06-08
IL69763A0 (en) 1983-12-30

Similar Documents

Publication Publication Date Title
DE3390212C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE3248900C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE3448360C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH653321A5 (de) 1alpha-hydroxylierte vitamin d-derivate und verfahren zu ihrer herstellung.
CH650237A5 (de) 1-fluorierte vitamin d verbindungen.
DE4141746A1 (de) 20-methyl-substituierte vitamin d-derivate
DE3590232C2 (de) 1,24-Dihydroxy- 22-Vitamin D3-Derivate, diese enthaltende Arzneimittel sowie Cholesterinderivate alsZwischenprodukte
DE3933034A1 (de) 24-homo-vitamin-d-derivate, verfahren zu ihrer herstellung
CH651295A5 (de) 25-hydroxy-26,26,26,27,27,27-hexafluorcholecalciferol.
CH662572A5 (de) Zur herstellung von 26,26,26,27,27,27-hexafluor-1alpha, 25-dihydroxycholesterin geeignete steroide.
DE4011682A1 (de) 24-oxa-derivate in der vitamin d-reihe
CH668258A5 (de) Hydroxyvitamin d2-isomere.
CH647760A5 (de) Verfahren zur herstellung von 1-hydroxycalciferolen und deren derivaten.
CH650240A5 (de) 24,24-difluor-1alpha,25-dihydroxycholecalciferol.
DE2326008C3 (de) Verfahren zur Herstellung von 25-Hydroxycholesterin und dessen Ester
DE3590488C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE3153427C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0441467B1 (de) Seitenketten-homologe Vitamin-D-Derivate, Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische Präparate, sowie deren Verwendung als Arzneimittel
EP0572489A1 (de) Ausgangsverbindungen zur herstellung von calcitriol sowie dessen abkömmlingen, verfahren zur herstellung dieser ausgangsverbindungen sowie zwischenprodukte für dieses verfahren.
DE3490427C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE2812741C2 (de) Vitamin D↓3↓-Derivate, Verfahren und Zwischenprodukte zu deren Herstellung und diese enthaltende Arzneimittel
DE69108319T2 (de) Verfahren zur herstellung von vitamin-d2-verbindungen und ihrer 1-alpha hydrogenierten derivate.
DE3590080C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH653004A5 (de) 1alpha-hydroxy-25-keto-27-nor-cholecalciferol.
CH635826A5 (de) Vitamin d(3)-derivate.

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
Q172 Divided out of (supplement):

Ref document number: 3348322

Country of ref document: DE

AC Divided out of

Ref document number: 3348322

Country of ref document: DE

AC Divided out of

Ref document number: 3348322

Country of ref document: DE

D2 Grant after examination
8364 No opposition during term of opposition